TITLE

Pneumocystis jiroveci pneumonia and pneumomediastinum in an anti-TNFα naive patient with ulcerative colitis

AUTHOR(S)
Lee, James C.; Bell, Deborah C.; Guinness, Richard M.; Ahmad, Tariq; Wexner, Steven D.; Kupcinskas, Limas
PUB. DATE
April 2009
SOURCE
World Journal of Gastroenterology;5/21/2009, Vol. 15 Issue 15, p1897
SOURCE TYPE
Academic Journal
DOC. TYPE
Case Study
ABSTRACT
We report the case of a 21-year-old man who was noted to have pneumomediastinum during an admission for an acute flare of ulcerative colitis. At that time, he was on maintenance treatment with azathioprine at a dose of 1.25 mg/kg per day, and had not received supplementary steroids for 9 mo. He had never received anti-tumor necrosis factor (TNF)α therapy. Shortly after apparently effective treatment with intravenous steroids and an increased dose of azathioprine, he developed worsening colitic and new respiratory symptoms, and was diagnosed with Pneumocystis jiroveci (carinii) pneumonia (PCP). Pneumomediastinum is rare in immunocompetent hosts, but is a recognized complication of PCP in human immunodeficiency virus (HIV) patients, although our patient's HIV test was negative. Treatment of PCP with co-trimoxazole resulted in resolution of both respiratory and gastrointestinal symptoms, without the need to increase the steroid dose. There is increasing vigilance for opportunistic infections in patients with inflammatory bowel disease following the advent of anti-TNFα therapy. This case emphasizes the importance of considering the possibility of such infections in all patients with inflammatory bowel disease, irrespective of the immunosuppressants they receive, and highlights the potential of steroid-responsive opportunistic infections to mimic worsening colitic symptoms in patients with ulcerative colitis.
ACCESSION #
42834298

 

Related Articles

  • Anti-tumor necrosis factor therapy in rheumatoid arthritis patients with a history of deep prosthetic joint infection: a report of four cases. Hirano, Yuji; Kojima, Toshihisa; Kanayama, Yasuhide; Shioura, Tomone; Hayashi, Masatoshi; Tsuboi, Seiji; Ishiguro, Naoki // Modern Rheumatology (Springer Science & Business Media B.V.);Oct2011, Vol. 21 Issue 5, p542 

    Four rheumatoid arthritis patients (three women and one man) who had a history of prosthetic joint infection were treated with anti-tumor necrosis factor (TNF) agents after treatment of the infection. The anti-TNF therapy was subsequently discontinued in three patients. The reason for...

  • β-Glucans Are Masked but Contribute to Pulmonary Inflammation During Pneumocystis Pneumonia. Kutty, Geetha; Davis, A. Sally; Ferreyra, Gabriela A.; Ju Qiu; Da Wei Huang; Sassi, Monica; Bishop, Lisa; Handley, Grace; Sherman, Brad; Lempicki, Richard; Kovacs, Joseph A.; Qiu, Ju; Huang, Da Wei // Journal of Infectious Diseases;9/1/2016, Vol. 214 Issue 5, p782 

    β-glucans, which can activate innate immune responses, are a major component in the cell wall of the cyst form of Pneumocystis In the current study, we examined whether β-1,3-glucans are masked by surface proteins in Pneumocystis and what role β-glucans play in Pneumocystis-associated...

  • Pneumocystis jirovecii pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of 15 cases and analysis of risk factors. Tanaka, Michi; Sakai, Ryoko; Koike, Ryuji; Komano, Yukiko; Nanki, Toshihiro; Sakai, Fumikazu; Sugiyama, Haruhito; Matsushima, Hidekazu; Kojima, Toshihisa; Ohta, Shuji; Ishibe, Yoji; Sawabe, Takuya; Ota, Yasuhiro; Ohishi, Kazuhisa; Miyazato, Hajime; Nonomura, Yoshinori; Saito, Kazuyoshi; Tanaka, Yoshiya; Nagasawa, Hayato; Takeuchi, Tsutomu // Modern Rheumatology (Springer Science & Business Media B.V.);Nov2012, Vol. 22 Issue 6, p849 

    Objectives: The association of anti-tumor necrosis factor therapy with opportunistic infections in rheumatoid arthritis (RA) patients has been reported. The goal of this study was to clarify the clinical characteristics and the risk factors of RA patients who developed Pneumocystis jirovecii...

  • Proinflammatory Th2 cytokines induce production of thymic stromal lymphopoietin in human colonic epithelial cells. Tanaka, Junya; Saga, Kazuyuki; Kido, Masahiro; Nishiura, Hisayo; Akamatsu, Takuji; Chiba, Tsutomu; Watanabe, Norihiko // Digestive Diseases & Sciences;Jul2010, Vol. 55 Issue 7, p1896 

    Purpose: Thymic stromal lymphopoietin (TSLP) is released by intestinal epithelial cells (IECs), and TSLP-conditioned dendritic cells appear to be involved in immune homeostasis of intestine and immunoglobulin A (IgA) class-switching in the physiological condition. In contrast, TSLP...

  • Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. Suzuki, Yasuo; Motoya, Satoshi; Hanai, Hiroyuki; Matsumoto, Takayuki; Hibi, Toshifumi; Robinson, Anne; Mostafa, Nael; Chao, Jingdong; Arora, Vipin; Camez, Anne; Thakkar, Roopal; Watanabe, Mamoru // Journal of Gastroenterology;Feb2014, Vol. 49 Issue 2, p283 

    Background: Adalimumab is a fully human, monoclonal antibody against tumor necrosis factor that is approved in Western countries for the treatment of moderately to severely active ulcerative colitis (UC). Methods: This 52-week, phase 2/3, randomized, double-blind study evaluated adalimumab for...

  • Predictors of Thiopurine Treatment Failure in Biologic-Naïve Ulcerative Colitis Patients. Thapa, Sudeep; Hadid, Hiba; Usman, Mohammed; Imam, Waseem; Hassan, Ahmad; Schairer, Jason; Jafri, Syed-Mohammed; Kaur, Nirmal; Thapa, Sudeep Dhoj; Jafri, Syed-Mohammed R // Digestive Diseases & Sciences;Jan2016, Vol. 61 Issue 1, p230 

    Introduction: Thiopurines (azathioprine and 6-mercaptopurine) have been used in the management of UC patients for over three decades. Nearly half of patients with UC treated with thiopurines fail to achieve remission or lose remission during treatment. Factors associated with...

  • Pneumocystis carinii pneumonia.  // Modern Medicine;Aug95, Vol. 63 Issue 8, p26 

    Reports on the US Food and Drug Administration's approval on the marketing of a suspension form of atovaquone in the treatment of pneumocystis carinii pneumonia. Advantages and convenience; Dosage.

  • Pneumocystis pneumonia--Los Angeles.  // MMWR: Morbidity & Mortality Weekly Report;8/30/1996, Vol. 45 Issue 34, p730 

    Reports on Pneumocystis pneumonia cases in Los Angeles, California, from October 1980 to May 1981. Patient profiles; Complications; Statistics.

  • Inhaled or Reduced-Dose Intravenous Pentamidine for Pneumocystis carinii Pneumonia. Conte Jr., John E.; Hollander, Harry; Golden, Jeffrey A. // Annals of Internal Medicine;Oct87, Vol. 107 Issue 4, p495 

    Presents a study which evaluated inhaled or inhaled pentamidine for the treatment of patients with mild Pneumocystis carinii pneumonia. Diagnostic considerations; Methodology of the study; Results.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics